Fierce Pharma August 29, 2024
It’s been two years since the Inflation Reduction Act (IRA) was passed, and, while the law’s Medicare-negotiated price cuts haven’t yet gone into effect, a change surrounding biosimilar reimbursement rates was instated in 2022.
The new provision was meant to dismantle financial disincentives to biosimilar adoption and save the U.S. healthcare system billions of dollars, but has the legislation worked to plan so far?
Drug development consultancy Certara sought to find out. In its “Boost or Bust?” report, the company surveyed oncology account staff at 79 healthcare facilities—including a mix of hospitals and community infusion sites—on their use of 17 biosimilar products targeting five reference medicines (Roche’s Avastin, Herceptin and Rituxan as well as Amgen’s Neupogen and Procrit).
On...
Today's Sponsors
Today's Sponsor